We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Technology Diagnoses Pneumonia Caused by Undetected Pathogens

By LabMedica International staff writers
Posted on 11 Oct 2017
A novel next-generation sequencing (NGS) test for respiratory infections has been launched. More...
The test provides a new solution for thousands of physicians who currently experience difficulty in diagnosing and treating patients with pneumonia and other respiratory diseases.

A strategic partnership was developed and commercialized novel infectious disease testing using metagenomics. This hypothesis-free approach to infectious disease testing uses DNA and RNA analysis to quickly identify bacteria, viruses, fungi, and parasites in patient samples.

The test detects more than 200 common and rare bacterial, fungal, and viral respiratory pathogens with a single test. By providing more comprehensive and actionable information within a clinically relevant turnaround time, this testing can help reduce inappropriate antibiotic use, avoid sequential testing, and potentially shorten hospital stays.

Diagnosing patients, particularly critically ill, immunocompromised patients, with suspected pneumonia can potentially require more than a dozen tests (including test panels) to determine the culprit pathogen. The novel test, known as Explify Respiratory, was developed by Arup Laboratories (Salt lake City, UT, USA) and IDbyDNA, Inc (San Francisco, CA, USA). The test is powered by IDbyDNA’s Taxonomer software, a DNA search engine that can rapidly identify any organism by its genetic material. In a study, Explify Respiratory identified pathogens missed by conventional laboratory tests in 44% of immunocompromised children treated in the intensive care unit (ICU) for pneumonia. In 67% of specimens, only one pathogen was detected. Pathogens included 13 bacteria; Klebsiella pneumoniae, Haemophilus influenzae, Staphylococcus aureus; seven fungi; Mucor spp., Fusarium spp., Pneumocystis jirovecii and viruses.

Robert Schlaberg, MD, Dr Med, MPH, a specialist in molecular infectious disease testing, said, “Current diagnostic techniques rely heavily on testing for suspected pathogens, which can be inconclusive and time-consuming. This technology can test for a very large number of pathogens at once, whether they are expected or not. A doctor doesn’t have to suspect the cause of a patient’s infection to direct the test ordering, but can instead simply ask, ‘What is my patient infected with?’” The study was originally presented at the 2017 American Thoracic Society Annual Meeting, held May 19-24, 2017, in Washington, DC, USA.

Related Links:
Arup Laboratories
IDbyDNA

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: GRAIL’s Galleri test uses machine learning to analyze cfDNA patterns for cancer signals and predict their likely location to guide further evaluation.

Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options

Many lethal cancers lack routine screening and are often diagnosed only after symptoms emerge, limiting curative options. Standard programs in the United States cover a small subset of malignancies, leaving... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.